Diagnosis and Management of Non-Infectious Uveitis in Pediatric Patients
Paediatr Drugs. 2023 Oct 4. doi: 10.1007/s40272-023-00596-5. Online ahead of print.ABSTRACTUveitis in children accounts for 5-10% of all cases. The causes vary considerably. Classically, uveitis is distinguished according to its infectious or inflammatory origin and whether it is part of a systemic disease or represents an isolated ocular disease. It is important to highlight the specificity of certain etiologies among children such as juvenile idiopathic arthritis. The development of visual function can potentially be hindered by amblyopia (children aged < 7 years), in addition to the usual complications (synechiae, ma...
Source: Paediatric Drugs - October 4, 2023 Category: Pediatrics Authors: Ai Tien Nguyen Isabelle Kon é-Paut Perrine Dusser Source Type: research
Diagnosis and Management of Non-Infectious Uveitis in Pediatric Patients
Paediatr Drugs. 2023 Oct 4. doi: 10.1007/s40272-023-00596-5. Online ahead of print.ABSTRACTUveitis in children accounts for 5-10% of all cases. The causes vary considerably. Classically, uveitis is distinguished according to its infectious or inflammatory origin and whether it is part of a systemic disease or represents an isolated ocular disease. It is important to highlight the specificity of certain etiologies among children such as juvenile idiopathic arthritis. The development of visual function can potentially be hindered by amblyopia (children aged < 7 years), in addition to the usual complications (synechiae, ma...
Source: Paediatric Drugs - October 4, 2023 Category: Pediatrics Authors: Ai Tien Nguyen Isabelle Kon é-Paut Perrine Dusser Source Type: research
Diagnosis and Management of Non-Infectious Uveitis in Pediatric Patients
Paediatr Drugs. 2023 Oct 4. doi: 10.1007/s40272-023-00596-5. Online ahead of print.ABSTRACTUveitis in children accounts for 5-10% of all cases. The causes vary considerably. Classically, uveitis is distinguished according to its infectious or inflammatory origin and whether it is part of a systemic disease or represents an isolated ocular disease. It is important to highlight the specificity of certain etiologies among children such as juvenile idiopathic arthritis. The development of visual function can potentially be hindered by amblyopia (children aged < 7 years), in addition to the usual complications (synechiae, ma...
Source: Paediatric Drugs - October 4, 2023 Category: Pediatrics Authors: Ai Tien Nguyen Isabelle Kon é-Paut Perrine Dusser Source Type: research
Diagnosis and Management of Non-Infectious Uveitis in Pediatric Patients
Paediatr Drugs. 2023 Oct 4. doi: 10.1007/s40272-023-00596-5. Online ahead of print.ABSTRACTUveitis in children accounts for 5-10% of all cases. The causes vary considerably. Classically, uveitis is distinguished according to its infectious or inflammatory origin and whether it is part of a systemic disease or represents an isolated ocular disease. It is important to highlight the specificity of certain etiologies among children such as juvenile idiopathic arthritis. The development of visual function can potentially be hindered by amblyopia (children aged < 7 years), in addition to the usual complications (synechiae, ma...
Source: Paediatric Drugs - October 4, 2023 Category: Pediatrics Authors: Ai Tien Nguyen Isabelle Kon é-Paut Perrine Dusser Source Type: research
Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease
Paediatr Drugs. 2023 Oct 3. doi: 10.1007/s40272-023-00593-8. Online ahead of print.ABSTRACTChronic lung disease in children with systemic juvenile idiopathic arthritis (SJIA-LD) is an emerging and potentially life-threatening disease complication. Despite recent descriptions of its clinical spectrum, preliminary immunologic characterization, and proposed hypotheses regaarding etiology, optimal approaches to diagnosis and management remain unclear. Here, we review the current clinical understanding of SJIA-LD, including the potential role of biologic therapy in disease pathogenesis, as well as the possibility of drug reacti...
Source: Paediatric Drugs - October 3, 2023 Category: Pediatrics Authors: Christopher Towe Alexei A Grom Grant S Schulert Source Type: research
Hidradenitis Suppurativa in Children and Adolescents: An Update on Pharmacologic Treatment Options
Paediatr Drugs. 2023 Oct 2. doi: 10.1007/s40272-023-00595-6. Online ahead of print.ABSTRACTHidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin condition that manifests as painful, deep-seated, inflamed nodules and abscesses in the axillary, groin, perianal, perineal, and inframammary regions. The associated pain, malodour, and disfigurement contribute to its profound negative impact on psychosocial spheres and overall quality of life in affected individuals. Although the symptoms of HS classically begin in the second or third decade of life, HS affects children and adolescents as well. Despite this, th...
Source: Paediatric Drugs - October 2, 2023 Category: Pediatrics Authors: Nicholas Chiang Cathryn Sibbald Rebecca Levy Irene Lara-Corrales Source Type: research
Hidradenitis Suppurativa in Children and Adolescents: An Update on Pharmacologic Treatment Options
Paediatr Drugs. 2023 Oct 2. doi: 10.1007/s40272-023-00595-6. Online ahead of print.ABSTRACTHidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin condition that manifests as painful, deep-seated, inflamed nodules and abscesses in the axillary, groin, perianal, perineal, and inframammary regions. The associated pain, malodour, and disfigurement contribute to its profound negative impact on psychosocial spheres and overall quality of life in affected individuals. Although the symptoms of HS classically begin in the second or third decade of life, HS affects children and adolescents as well. Despite this, th...
Source: Paediatric Drugs - October 2, 2023 Category: Pediatrics Authors: Nicholas Chiang Cathryn Sibbald Rebecca Levy Irene Lara-Corrales Source Type: research
Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward
Paediatr Drugs. 2023 Sep 29. doi: 10.1007/s40272-023-00594-7. Online ahead of print.ABSTRACTOver the last decade, there has been an increase in the use of targeted therapy using small molecules such as Janus kinase (JAK) inhibitors. Since the introduction of ruxolitinib, the first non-selective JAK inhibitor approved for use in myelofibrosis, many other JAK inhibitors have been tried in a wide spectrum of immune-mediated disorders. Although various trials have shown the promising efficacy of JAK inhibitors in immune-mediated inflammatory disorders (IMIDs), there is a growing concern over the major cardiovascular events and...
Source: Paediatric Drugs - September 29, 2023 Category: Pediatrics Authors: Narendra Kumar Bagri Christine Chew A V Ramanan Source Type: research
Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward
Paediatr Drugs. 2023 Sep 29. doi: 10.1007/s40272-023-00594-7. Online ahead of print.ABSTRACTOver the last decade, there has been an increase in the use of targeted therapy using small molecules such as Janus kinase (JAK) inhibitors. Since the introduction of ruxolitinib, the first non-selective JAK inhibitor approved for use in myelofibrosis, many other JAK inhibitors have been tried in a wide spectrum of immune-mediated disorders. Although various trials have shown the promising efficacy of JAK inhibitors in immune-mediated inflammatory disorders (IMIDs), there is a growing concern over the major cardiovascular events and...
Source: Paediatric Drugs - September 29, 2023 Category: Pediatrics Authors: Narendra Kumar Bagri Christine Chew A V Ramanan Source Type: research
Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward
Paediatr Drugs. 2023 Sep 29. doi: 10.1007/s40272-023-00594-7. Online ahead of print.ABSTRACTOver the last decade, there has been an increase in the use of targeted therapy using small molecules such as Janus kinase (JAK) inhibitors. Since the introduction of ruxolitinib, the first non-selective JAK inhibitor approved for use in myelofibrosis, many other JAK inhibitors have been tried in a wide spectrum of immune-mediated disorders. Although various trials have shown the promising efficacy of JAK inhibitors in immune-mediated inflammatory disorders (IMIDs), there is a growing concern over the major cardiovascular events and...
Source: Paediatric Drugs - September 29, 2023 Category: Pediatrics Authors: Narendra Kumar Bagri Christine Chew A V Ramanan Source Type: research
Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial
CONCLUSIONS: The use of a low dose of remifentanil before cord clamping for a Cesarean section appears to be safe both for the mother and the preterm newborn, but it does not improve maternal or neonatal outcomes.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT02029898.PMID:37713021 | DOI:10.1007/s40272-023-00591-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - September 15, 2023 Category: Pediatrics Authors: Cl ément Chollat Fabien Tourrel Estelle Houivet Romain Gillet Eric Verspyck Maryline Lecointre St éphane Marret Vincent Comp ère Source Type: research
Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial
CONCLUSIONS: The use of a low dose of remifentanil before cord clamping for a Cesarean section appears to be safe both for the mother and the preterm newborn, but it does not improve maternal or neonatal outcomes.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT02029898.PMID:37713021 | DOI:10.1007/s40272-023-00591-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - September 15, 2023 Category: Pediatrics Authors: Cl ément Chollat Fabien Tourrel Estelle Houivet Romain Gillet Eric Verspyck Maryline Lecointre St éphane Marret Vincent Comp ère Source Type: research
Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial
CONCLUSIONS: The use of a low dose of remifentanil before cord clamping for a Cesarean section appears to be safe both for the mother and the preterm newborn, but it does not improve maternal or neonatal outcomes.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT02029898.PMID:37713021 | DOI:10.1007/s40272-023-00591-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - September 15, 2023 Category: Pediatrics Authors: Cl ément Chollat Fabien Tourrel Estelle Houivet Romain Gillet Eric Verspyck Maryline Lecointre St éphane Marret Vincent Comp ère Source Type: research
Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial
CONCLUSIONS: The use of a low dose of remifentanil before cord clamping for a Cesarean section appears to be safe both for the mother and the preterm newborn, but it does not improve maternal or neonatal outcomes.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT02029898.PMID:37713021 | DOI:10.1007/s40272-023-00591-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - September 15, 2023 Category: Pediatrics Authors: Cl ément Chollat Fabien Tourrel Estelle Houivet Romain Gillet Eric Verspyck Maryline Lecointre St éphane Marret Vincent Comp ère Source Type: research
Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial
CONCLUSIONS: The use of a low dose of remifentanil before cord clamping for a Cesarean section appears to be safe both for the mother and the preterm newborn, but it does not improve maternal or neonatal outcomes.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT02029898.PMID:37713021 | DOI:10.1007/s40272-023-00591-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - September 15, 2023 Category: Pediatrics Authors: Cl ément Chollat Fabien Tourrel Estelle Houivet Romain Gillet Eric Verspyck Maryline Lecointre St éphane Marret Vincent Comp ère Source Type: research
